Forty Seven Revenue and Competitors
Estimated Revenue & Valuation
- Forty Seven's estimated annual revenue is currently $7.4M per year.
- Forty Seven received $75.0M in venture funding in October 2017.
- Forty Seven's estimated revenue per employee is $354,286
- Forty Seven's total funding is $156M.
Employee Data
- Forty Seven has 21 Employees.
- Forty Seven grew their employee count by 24% last year.
Forty Seven's People
| Name | Title | Email/Phone |
|---|
Forty Seven Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Forty Seven?
With a passion for helping patients defeat their cancer, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.
keywords:N/A
$156M
Total Funding
21
Number of Employees
$7.4M
Revenue (est)
24%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Forty Seven News
(fifteen, sixteen, twenty-two, twenty-three, twenty-seven) ... (seven, eleven, thirty-six, forty-three, forty-six, fifty; Extra Shot: five).
... twenty-seven, thirty-three, thirty-seven, forty-four, forty-five, forty-seven, forty-eight, fifty-two, fifty-four, fifty-eight,...
(three, five, six, seven, twelve, eighteen, nineteen, twenty-three, ... thirty-three, forty-three, forty-six, forty-seven, fifty-seven,...
Gilead Sciences, Inc. (Nasdaq: GILD) is to acquire Forty Seven, Inc. (Nasdaq: FTSV), a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University, for $9 ...
Forty Seven’s lead product candidate is magrolimab, a monoclonal antibody targeting the cell-surface protein CD47 in Phase Ib development for blood cancers like acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and diffuse large B-cell lymphoma (DLBCL). “This agreement builds on Gile ...
Other Companies in Menlo Park
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.1M | 21 | 0% | N/A |
#2 | $2.1M | 21 | -22% | N/A |
#3 | $2.1M | 21 | N/A | N/A |
#4 | $7.5M | 21 | 5% | $390.1M |
#5 | $15M | 21 | -19% | N/A |
Forty Seven Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2016-02-25 | $75.0M | A | Lightspeed Venture Partners | Article |
| 2017-10-18 | $75.0M | B | Wellington Management Company LLP | Article |